Literature DB >> 30481382

Hospital at Home-Plus: A Platform of Facility-Based Care.

Linda V DeCherrie1,2, Ania Wajnberg1,2, Tacara Soones3, Christian Escobar1,2, Elisse Catalan1, Sara Lubetsky1, Bruce Leff4, Alex Federman2, Albert Siu1.   

Abstract

OBJECTIVES: To describe the evolution of a hospital at home (HaH) program to a HaH with a 30-day posthospitalization transition period (HaH-Plus) and results of a retrospective review of cases.
DESIGN: After launching HaH-Plus, we used the same interdisciplinary clinical team to provide acute home-based care for a broader range of home-based acute-level services than originally conceived in the Hospital at Home model. These included a palliative care unit at home (PCUaH), an observation unit at home (OUaH), a post-acute care rehabilitation at home (RaH), and a program for the hospital averse - those patients needing to be in the hospital but who refuse.
SETTING: Urban health system. PARTICIPANTS: Individuals 18 years or older residing in specified catchment area with Medicare fee-for-service or accepted Medicare/Medicaid Advantage plans requiring facility-based care. INTERVENTION: Provision of facility-based acute-level care at home to 685 participants. MEASUREMENTS: Length of stay, readmission, and mortality.
RESULTS: HaH-Plus cared for 685 individuals. The PCUaH had the oldest participants (mean age 87), and all groups were predominantly female and dually eligible for Medicare and Medicaid. Diagnoses and length of stay were similar in all groups except that those in RaH had a larger group of diagnoses, than those accepted in to HaH-Plus and those in OUaH had a shorter stay. Rate of readmission was highest for RaH (19%). Mortality during the active treatment episode was highest for PCUaH and hospital averse as compared to HaH-Plus, OUaH and RaH.
CONCLUSION: Providing a broader range of facility-based care in the home has significant advantages for patients and increases the scalability of HaH. Developing a spectrum of services was possible by leveraging a robust, 24-hour HaH team. Community- and home-based care could become a greater part of the U.S. healthcare system if a platform of HaH services along with advances in technology and payment models were developed. J Am Geriatr Soc 67:596-602, 2019.
© 2018 The American Geriatrics Society.

Entities:  

Keywords:  home-based medical care; hospital at home; postacute care

Year:  2018        PMID: 30481382     DOI: 10.1111/jgs.15653

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  5 in total

1.  "What Would It Take to Transform Post-Acute Care?" 2019 Conference Proceedings on Re-envisioning Post-Acute Care.

Authors:  Christine D Jones; Kathryn A Nearing; Robert E Burke; Hillary D Lum; Rebecca S Boxer; Jennifer E Stevens-Lapsley; Mustafa Ozkaynak; Cari R Levy
Journal:  J Am Med Dir Assoc       Date:  2020-03-17       Impact factor: 4.669

2.  Multiple chronic conditions at a major urban health system: a retrospective cross-sectional analysis of frequencies, costs and comorbidity patterns.

Authors:  Usnish B Majumdar; Christophe Hunt; Patrick Doupe; Aaron J Baum; David J Heller; Erica L Levine; Rashi Kumar; Robert Futterman; Cother Hajat; Sandeep P Kishore
Journal:  BMJ Open       Date:  2019-10-15       Impact factor: 2.692

3.  A research agenda for hospital at home.

Authors:  Bruce Leff; Linda V DeCherrie; Michael Montalto; David M Levine
Journal:  J Am Geriatr Soc       Date:  2022-02-24       Impact factor: 7.538

4.  Geriatric home-based rehabilitation in Australia: Preliminary data from an inpatient bed-substitution model.

Authors:  Paula M Loveland; Esmee M Reijnierse; Louis Island; Wen Kwang Lim; Andrea B Maier
Journal:  J Am Geriatr Soc       Date:  2022-02-04       Impact factor: 7.538

5.  Adapting a Hospital-at-Home Care Model to Respond to New York City's COVID-19 Crisis.

Authors:  David J Heller; Katherine A Ornstein; Linda V DeCherrie; Pamela Saenger; Fred C Ko; Carl-Philippe Rousseau; Albert L Siu
Journal:  J Am Geriatr Soc       Date:  2020-08-13       Impact factor: 7.538

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.